Figure 2.

Vaccine efficacy against first or only episode of HZ by age and follow-up year in (A) ZOE-50 Asian population ≥50 YOA and (B) pooled ZOE-50/70 Asian population ≥70 YOA (modified total vaccinated cohort)

HZ, herpes zoster; RZV, participants receiving the adjuvanted recombinant zoster vaccine; Placebo, participants receiving placebo; YOA, years of age; N, number of participants; n, number of confirmed HZ episodes. *vaccine efficacy adjusted by age strata; ^#vaccine efficacy adjusted by age strata and region. Year 1, from 30 days to 395 days post-dose 2; Year 2, from >395 days to 760 days post-dose 2; Year 3, from >760 days to 1125 days post-dose 2; Year 4, from >1125 days post-dose 2 until last contact date. Error bars depict 95% confidence intervals.